Conference abstract · 10 Mar 2025
CommentaryPublished 15 Feb 2007
Why Not Clozapine?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Clozapine is the only antipsychotic medication approved for treatment-resistant schizophrenia. The superiority of this second-line antipsychotic for reducing positive psychotic symptoms compared to other antipsychotics in treatment-resistant schizophrenia is well established. Clozapine is also effective for reducing suicide risk and physical aggression, reducing hospitalizations and overall treatment costs, improving quality of life and is associated with a longer treatment duration compared to most other antipsychotic agents. Despite these positive attributes, the prescription of clozapine in the U.S. is infrequent and disproportionately low relative to the estimated prevalence of treatment-resistant schizophrenia. In fact, use of clozapine in the U.S. accounts for approximately 5% of all antipsychotic prescriptions and is much less widely used than in other countries. Many possible explanations likely contribute to clozapine’s underuse in the U.S. including the potential for serious side effects. However, new advances in genetic testing that may help predict risk for agranulocytosis may soon make clozapine a more viable treatment option. Efforts to understand the apparent under prescribing of clozapine and to provide education and interventions to optimize its use in appropriate patients should be undertaken.
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Mini review · 29 May 2023
Elevated Landminus;aminoisobutyric Acid Aids to the Pathophysiology of Treatmentandminus;Resistant Schizophrenia and Clozapine Adverse Effects
Mini review · 2023
Elevated L−aminoisobutyric Acid Aids to the Pathophysiology of Treatment−Resistant Schizophrenia and Clozapine Adverse Effects
Short communication · 24 Jul 2022
Mitochondrial dysfunction of Clozapine attenuation, inflammatory gene expression, and behavioural abnormalities in an animal model of schizophrenia
Editorial · 30 Jul 2021
Effect of Clozapine in Schizophrenia
More from this journal
The newest in Clinical Schizophrenia & Related Psychoses.
Article · 18 Mar 2026
Antipsychotics vs. ECT with Antipsychotics: A PANSS and SCORS Investigation in Paranoid Schizophrenia
Article · 30 Sep 2025
Successful Treatment of a Treatment Refractory Patient with Clozapine Retrial
Article · 24 Jun 2025
Check the Necessity of Performing A CT Scan of the Brain in Patients with Mild Trauma
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Schizophrenia & Related Psychoses
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Deanna L. Kelly”
- BylineArticles whose byline prints “Julie Kreyenbuhl”
- BylineArticles whose byline prints “Robert W. Buchanan”
- BylineArticles whose byline prints “Anil K. Malhotra”

